ENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE OF ACETYL SALICYLIC ACID VIA CO-CRYSTALLIZATION TECHNIQUE: A NOVEL ASA-VALINE COCRYSTAL

SHANTHALA H. K.1a, JAYAPRAKASH H. V.1b, MUNIGANTI RADHAKRISHNA2a, JASWANTH GOWDA B. H.2, KARTHIKA PAUL3, S. J. SHANKAR4, MOHAMMED GULZAR AHMED4, SANJANA A.4

1aDepartment of Chemistry, Sri Siddhartha Academy of Higher Education, Tumkur, India 572107, 1bDepartment of Chemistry, Sri Siddhartha Institute of Technology, Tumkur, India 572105, 2Department of Pharmacy, Yenepoya Pharmacy College and Research Centre, Yenepoya (Deemed to be University), Mangaluru, India 575018, 3Department of Pharmaceutical Sciences, Vivekananda College of Pharmacy, Dr. Rajkumar Road, Rajajinagar 2nd Stage, Bengaluru, India 560055

Received: 20 Oct 2020, Revised and Accepted: 26 Nov 2020

Abstract

Objective: This study aims to synthesize acetylsalicylic acid (ASA) cocrystals using valine as a coformer via a co-crystallization technique to increase the solubility and dissolution rate of ASA.

Methods: The ASA-valine cocrystal (1:1 molar ratio) was prepared using the solvent evaporation technique with ethanol: water (50:50). The cocrystal was characterized using Fourier transform infrared spectroscopy (FT-IR), Differential scanning calorimetry (DSC), Powder X-ray diffraction (PXRD), Scanning electron microscopy (SEM), melting point to confirm the formation of cocrystal. The evaluation of cocrystal was done by drug content determination, solubility and dissolution studies.

Results: The prepared cocrystal was successfully confirmed for the formation of a hydrogen bond. The melting point of prepared cocrystal was decreased compared to pure ASA and valine, which indicated the formation of a new crystalline form. The FT-IR studies showed the formation of a new hydrogen bond by shifting the -O-H, C=O and -N-H functional groups. SEM studies ensured that the prepared cocrystals were in needle-like resultant by aqueous solubility and dissolution rate; thus, poor solubility of pure drugs is one of the significant thrust prompted by new technological advancements in pharmaceutical industries is to improve the fundamental properties of an API, such as solubility, flow properties, bioavailability, and physical and chemical stability [1]. As per the reports, nearly 40% of drugs are available in the market, and almost 90% of drugs still in the developmental pipeline are facing solubility issues [2]. The poor aqueous solubility of pure drugs is one of the vital issues encountered while developing the pharmaceutical formulations administered through oral and transdermal routes [3, 4]. The bioavailability of drugs that are administered orally can be resultant by aqueous solubility and dissolution rate; thus, poor aqueous solubility can be the stepping stone of inadequate and variable absorption of these drugs making the absorption process solely dependent on aqueous solubility [5, 6]. Thus, to overcome the solubility issue of poorly aqueous soluble drugs, new solid-state forms of old drugs utilizing a variety of solubility enhancement techniques such as salification, cocrystallization, etc. are being looked into, which modifies the physicochemical properties of a drug without changing its pharmacological activity [7-9].

Since the physicochemical properties are often dependent on the crystal structure of drugs, many have reported that the crystal engineering of drugs helps overcome issues related to solubility and thermodynamic stability [10, 11]. The synthesis of cocrystal is one of the significant strategies to improve the physicochemical parameters of pure drug. From the past 15 y, research towards pharmaceutical cocrystals has doubled. They have gained tremendous ability to modify not only ionizable drugs like salts but also non-ionizable drugs or weakly ionizable drugs [12-16]. Cocrystals are solid crystalline materials comprised of two or more non-ionizable drugs or weakly ionizable drugs [12-16]. Cocrystals are solid crystalline materials comprised of two or more non-ionizable drugs or weakly ionizable drugs [12-16]. Cocrystals are solid crystalline materials comprised of two or more non-ionizable drugs or weakly ionizable drugs [12-16]. Cocrystals are solid crystalline materials comprised of two or more non-ionizable drugs or weakly ionizable drugs [12-16]. Cocrystals are solid crystalline materials comprised of two or more non-ionizable drugs or weakly ionizable drugs [12-16].
impeccable potentiality in the formation of a hydrogen bond between the pure ASA fig. 2. Further, crystal structure characterizations, intermolecular interactions, thermal behaviors and dissolution behaviors of cocrystals were investigated using FT-IR, DSC, SEM, PXRD, solubility studies and in vitro dissolution studies. The main goal of this study is to not only synthesize cocrystals of ASA with improved solubility and dissolution rate but also to furnish new insight into the design of cocrystals using valine as conformers, which is believed to construct potential cocrystals by forming non-ionic interactions between pure drugs.

![Structural formula of acetylsalicylic acid (ASA)](image1)

**Fig. 1: Structural formula of acetylsalicylic acid (ASA)**

**Materials and Methods**

**Materials**

Acetylsalicylic acid (Aspirin) was purchased from Vasa Scientific Company (Bangalore, India). Valine of analytical grade was purchased from Central Drug House Pvt. Ltd. (Karnataka, India). Absolute ethanol was purchased from Vasa Scientific Company (Bangalore, India). All chemicals were used as received without any further purification.

**Preparation of cocrystals**

Acetylsalicylic acid (540 mg) and valine (351 mg) (1:1 molar ratio) were ground by using the high energy vibrational mill into a finely ground state (CMTT-200, Japan) for about 3-5 min, further transferred into a 25 ml glass beaker and added 20 ml of 50% ethanol-water mixture. The mixture was stirred until a clear solution was obtained. Thereafter, allowed to crystallize at room temperature by slow evaporation for 10 d. White coloured crystals were obtained at the end of the 10th d.

**Drug content determination**

ASA-valine cocrystal equivalent to 10 mg of pure ASA was taken separately into a 100 ml volumetric flask. The contents in the flask were dissolved in absolute ethanol. From the resultant solution 1 ml of solution taken and diluted to 10 ml of absolute ethanol. The absorbance of the resultant solution was recorded at 268 nm using UV-1700 double beam spectrophotometer (Shimadzu, Japan). The average of three readings was taken [39].

**Melting point study**

Melting points of the pure ASA, valine and ASA-valine cocrystal were measured using a Digital Melting temperature apparatus (Secor, Japan). The samples were weighed accurately (2 to 3 mg) and placed in hermetically sealed 40 ml aluminium crucibles, scanned from 25-300 °C at a heating rate of 10°C/min under a dry nitrogen atmosphere [42].

**RESULTS AND DISCUSSION**

**Drug content determination**

The drug content in the prepared ASA-Valine cocrystal was found to be 95.3%. Since some of the product was retained in the beaker as conformers, which is believed to construct potential cocrystals by forming non-ionic interactions between pure drugs.

**Scanning electron microscopy**

The surface characteristics and shape of the ASA-valine co-crystals were analyzed by Scanning Electron Microscopy (SEM) (Joel Jsm-5600, Japan). The samples for scanning electron microscopy were prepared by gently spreading the co-crystals on a double adhesive tape, which is stuck to an aluminum stub. The samples were then imaged using a 20 kV electron beam [41].

**Differential scanning calorimetry**

The Differential Scanning Calorimetry (DSC) analysis was conducted on a 2910 Modulated DSC V4.4E instrument (USA). The samples were weighed accurately (2 to 3 mg) and placed in hermetically sealed 40 ml aluminium crucibles, scanned from 25-300 °C at a heating rate of 10°C/min under a dry nitrogen atmosphere [42].

**Powder x-ray diffraction**

The Powder X-Ray Diffraction (PXRD) patterns were collected on a Shimadzu XRD-7000 X-ray diffractometer (Japan) maxima with Cu-Kα radiation (1.54 Å). The tube voltage and amperage were set at 20 kV and 35 mA, respectively. Each sample was scanned between 5 and 60° 2θ with a step size of 0.02°. Before performing the experiments, the instrument was calibrated using a silicon standard [43].

**Solubility study**

The solubility of ASA-valine cocrystal was determined by adding excess amounts of cocrystals in a Schott Duran bottle containing 5 ml of pH 4.5 acetate buffer solutions. The mixture was stirred continuously at 25±0.5 °C for 48 h to achieve equilibrium. The resultant solution was filtered using a whatman filter paper. The supernatant was then diluted to make sure that the solution concentration point falls on the standard curve. The filtrate was analyzed by UV-1700 double beam spectrophotometer (Shimadzu, Japan) at 268 nm after suitable dilution. The absorbance of the solution was taken as the solubility of the ASA in terms of concentration.

**In vitro dissolution study**

The dissolution test was carried out in a USP type 1 apparatus (Basket method). The samples were placed in size 00 hard gelatin capsules. 900 ml of pH 4.5 acetate buffer was used as dissolution media at 37±0.5 °C temperature and maintaining the stirring speed at 50 rpm. The samples were drawn at the interval of 5, 10, 15, 20, 25, 30, 45, 60, 90, and 120 min. Further fresh volume of the dissolution medium was replaced with the withdrawn volume to maintain the sink conditions. Samples withdrawn were analyzed at wavelength 268 nm using UV-1700 double beam spectrophotometer (Shimadzu, Japan) for determining the percentage of cumulative drug release [44].

**Materials and Methods**

**Materials**

Acetylsalicylic acid (Aspirin) was purchased from Vasa Scientific Company (Bangalore, India). Valine of analytical grade was purchased from Central Drug House Pvt. Ltd. (Karnataka, India). Absolute ethanol was purchased from Vasa Scientific Company (Bangalore, India). All chemicals were used as received without any further purification.

**Preparation of cocrystals**

Acetylsalicylic acid (540 mg) and valine (351 mg) (1:1 molar ratio) were ground by using the high energy vibrational mill into a finely ground state (CMTT-200, Japan) for about 3-5 min, further transferred into a 25 ml glass beaker and added 20 ml of 50% ethanol-water mixture. The mixture was stirred until a clear solution was obtained. Thereafter, allowed to crystallize at room temperature by slow evaporation for 10 d. White coloured crystals were obtained at the end of the 10th d.

**Drug content determination**

ASA-valine cocrystal equivalent to 10 mg of pure ASA was taken separately into a 100 ml volumetric flask. The contents in the flask were dissolved in absolute ethanol. From the resultant solution 1 ml of solution taken and diluted to 10 ml of absolute ethanol. The absorbance of the resultant solution was recorded at 268 nm using UV-1700 double beam spectrophotometer (Shimadzu, Japan). The average of three readings was taken [39].

**Melting point study**

Melting points of the pure ASA, valine and ASA-valine cocrystal were measured using a Digital Melting temperature apparatus (Secor, India).

**Fourier transform infrared spectroscopy**

The Fourier Transform Infrared Spectroscopy (FT-IR) spectral analysis was identified as an additional channel to manifest the development of cocrystals. The distinct and novel peaks in the FT-IR spectra of cocrystals were indicative of the formation of new intermolecular hydrogen bonding. FT-IR spectrums of cocrystals were recorded on a Perkin Elmer FT-IR spectrophotometer (USA) using the KBr pellet method in the spectral range 4000-500 cm⁻¹ with a resolution of 2 cm⁻¹ [40].

**Scanning electron microscopy**

The surface characteristics and shape of the ASA-valine co-crystals were analyzed by Scanning Electron Microscopy (SEM) (Joel Jsm-5600, Japan). The samples for scanning electron microscopy were prepared by gently spreading the co-crystals on a double adhesive tape, which is stuck to an aluminum stub. The samples were then imaged using a 20 kV electron beam [41].

**Differential scanning calorimetry**

The Differential Scanning Calorimetry (DSC) analysis was conducted on a 2910 Modulated DSC V4.4E instrument (USA). The samples were weighed accurately (2 to 3 mg) and placed in hermetically sealed 40 ml aluminium crucibles, scanned from 25-300 °C at a heating rate of 10°C/min under a dry nitrogen atmosphere [42].

**Powder x-ray diffraction**

The Powder X-Ray Diffraction (PXRD) patterns were collected on a Shimadzu XRD-7000 X-ray diffractometer (Japan) maxima with Cu-Kα radiation (1.54 Å). The tube voltage and amperage were set at 20 kV and 35 mA, respectively. Each sample was scanned between 5 and 60° 2θ with a step size of 0.02°. Before performing the experiments, the instrument was calibrated using a silicon standard [43].

**Solubility study**

The solubility of ASA-valine cocrystal was determined by adding excess amounts of cocrystals in a Schott Duran bottle containing 5 ml of pH 4.5 acetate buffer solutions. The mixture was stirred continuously at 25±0.5 °C for 48 h to achieve equilibrium. The resultant solution was filtered using a whatman filter paper. The supernatant was then diluted to make sure that the solution concentration point falls on the standard curve. The filtrate was analyzed by UV-1700 double beam spectrophotometer (Shimadzu, Japan) at 268 nm after suitable dilution. The absorbance of the solution was taken as the solubility of the ASA in terms of concentration.

**In vitro dissolution study**

The dissolution test was carried out in a USP type 1 apparatus (Basket method). The samples were placed in size 00 hard gelatin capsules. 900 ml of pH 4.5 acetate buffer was used as dissolution media at 37±0.5 °C temperature and maintaining the stirring speed at 50 rpm. The samples were drawn at the interval of 5, 10, 15, 20, 25, 30, 45, 60, 90, and 120 min. Further fresh volume of the dissolution medium was replaced with the withdrawn volume to maintain the sink conditions. Samples withdrawn were analyzed at wavelength 268 nm using UV-1700 double beam spectrophotometer (Shimadzu, Japan) for determining the percentage of cumulative drug release [44].
carbonyl stretching frequency was observed for ASA-valine cocrystal. This indicated the carbonyl groups in both ASA and valine remain untouched. A considerable shift in amine/hydroxyl stretching frequency was observed for ASA-valine cocrystal, which confirms the formation of a hydrogen bond between ASA and valine. The detailed stretching frequency of ASA and the prepared cocrystals are shown in table 2. The FT-IR spectra of pure ASA and ASA-valine cocrystal are shown in fig. 3, 4.

Table 1: Melting point of pure ASA, valine and ASA-valine cocrystal

| S. No. | Sample                  | Mean melting point (°C)±SD |
|--------|-------------------------|----------------------------|
| 1      | ASA                     | 133±04                     |
| 2      | Valine                  | 294±02                     |
| 3      | ASA-valine cocrystal    | 127±04                     |

*All values are expressed as mean±SD, (n=3).

Table 2: FT-IR stretching frequencies of ASA and ASA-valine cocrystals

| S. No. | Type of band | ASA (cm⁻¹) | ASA-valine cocrystal (cm⁻¹) |
|--------|--------------|------------|----------------------------|
| 1      | -O-H (st)    | 3430 (s)   | 3466 (vs)                  |
| 2      | -C=O (st)    | 1594 (vs)  | 1594 (vs)                  |
| 3      | -N-H (st)    | -          | 3255 (m)                   |

*(vs):-very strong; (s):-strong; (m):-medium; (st):-stretching.

Fig. 3: FT-IR spectra of pure ASA

Fig. 4: FT-IR spectra of ASA-valine cocrystal
Scanning electron microscopy

The surface morphology and appearance of the ASA-valine cocrystal was examined by SEM. As observed from the SEM images, the crystals were in needle-like appearance. The image of ASA-valine was shown in fig. 5.

Differential scanning calorimetry

DSC analysis of the synthesized cocrystals was performed to determine the exact melting temperature and to correlate the melting temperature with crystal density and intermolecular interactions. It is known that the melting temperature of the cocrystal often falls between the melting temperature of starting materials or below the starting material melting point [46]. In the present work, the ASA-valine cocrystal was found to melt exactly in between the melting temperature of pure ASA and valine as shown in fig. 6. At the temperature range of 120 °C, the decomposition of ASA-valine was observed, which corresponds to the mass change of 57% that assigned the separation of valine from ASA due to the breakage of a hydrogen bond between ASA-valine cocrystal.

Powder x-ray diffraction

PXRD is a reliable technique to characterize the formation of a new crystalline phase in solid-state. A different PXRD pattern of the product after cocrystallization experiments from the individual components confirms the formation of a new crystalline phase [47]. The PXRD patterns for ASA and ASA-valine cocrystal are shown in fig. 7, 8. ASA exhibited characteristic crystalline peaks at 2θ values of 11°, 16°, 18°, 23.5°, 29.5°, 31.5°, 32.5° and 40°, whereas ASA-valine cocrystal exhibited characteristic crystalline peaks at 2θ values of 10.5°, 17.5°, 28°, 32° and 36°. The different peaks in the cocrystal’s PXRD pattern could imply the existence of interactions between ASA and valine to form a new cocrystalline phase.
The solubility of ASA-valine cocrystal was performed in a pH 4.5 acetate buffer solution. The pure ASA exhibited a solubility of 3 mg/ml. The ASA-valine cocrystal showed an increased solubility of 17 mg/ml compared to pure ASA. This is due to the formation of a hydrogen bond between ASA and valine. Due to the presence of a hydrophilic chain in the cocrystal, solubility has increased to a greater extent.

**In vitro dissolution study**

The in vitro drug release study of ASA-valine by USP type 1 apparatus (Basket method). The cocrystal was placed in a size 00 hard gelatin capsule. The dissolution media was filled with 900 ml of pH 4.5 acetate buffer solution maintained at temperature 37±0.5 °C with a stirring speed of 50 rpm. The samples were drawn at the interval of 5, 10, 15, 20, 25, 30, 45, 60, 90, and 120 min. The drug release of ASA-valine cocrystal was found to be 100% at 60th min. Where in the case of pure ASA and marketed product of ASA exhibited the dissolution rate of 59% and 69% at 60th min, respectively. The increase in dissolution rate of ASA-valine cocrystal may be due to strong intermolecular hydrogen bonding between ASA and valine. This is due to the presence of free carboxylic acid and amine functional groups in the valine. Nevertheless, the hydrophilic group present in the valine is responsible for the formation of hydrophilic ends in the ASA-valine cocrystals. Thus, the ASA-valine cocrystal showed a 1.7 and 1.44 folds increase in dissolution rate compared to pure ASA and marketed product of ASA, respectively as shown in fig. 9.
CONCLUSION

Co-crystallization technique can be an efficient technique for enhancement of the solubility and dissolution rate of BCS class 2 drugs. In this study, a novel cocrystal of ASA-valine was synthesized using the solvent evaporation technique and characterized. The melting of the prepared cocrystal remained lesser than the pure ASA, thus confirming the formation of a new crystalline form. The FT-IR, DSC and PXRD studies revealed the successful formation of cocrystals. The surface morphology by using SEM revealed the formation of needle-like crystals. The dissolution studies exhibited an increased dissolution rate compared to pure ASA and marketed ASA. Thus the ASA-valine cocrystal can be a greater alternative for increased solubility and dissolution rate compared to pure ASA.

ACKNOWLEDGEMENT

The authors would like to thank the SSIT Research Centre, Tumkur for providing the facilities to carry out this research work.

FUNDING

Nil

AUTHORS CONTRIBUTIONS

All the authors have contributed equally.

CONFLICTS OF INTERESTS

The authors declare no conflict of interest.

REFERENCES

1. Taylor D. The pharmaceutical industry and the future of drug development. Pharmaceuticals in the Environment; 2015. p. 1-33. DOI:10.1039/9781782622234-00001.
2. Singh A, Worku ZA, Van den Mooter G. Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opin Drug Delivery 2011;8:1-361-78.
3. Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B 2015;5:442-53.
4. Shankar SJ, Gowda BHJ, Akshatha RS, Metikurki B, Rehamathulla M. A review on the role of nanocrystals and nanosuspensions in drug delivery systems. Int J Appl Pharm 2019;12:10-6.
5. Cherniakov I, Domb AJ, Hoffman A. Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects. Expert Opin Drug Delivery 2015;12:1-121-33.
6. Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodriguez Hornedo N. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm 2013;453:101-25.
7. Kuminek G, Cao F, Bahia de Oliveira da Rocha A, Gonçalves Cardoso S, Rodriguez Hornedo N. Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5. Adv Drug Delivery Rev 2016;101:1-143-66.
8. Domingos S, Andre V, Quaresma S, Martins IC, Minas da Piedade MF, Duarte MT. New forms of old drugs: improving without changing. J Pharm Pharmacol 2015;67:830-46.
9. Chadha R, Saini A, Arora P, Bhandari S. Pharmaceutical cocrystals: a novel approach for oral bioavailability enhancement of drugs. Crit Rev Ther Drug Carrier Syst 2012;29:183-218.
10. Seddon KR, Zaworotko M. Crystal engineering: the design and application of functional solids, Kluwer Academic Publishers, The Netherlands; 1999.
11. Yamamoto K, Kojima T, Karashima M, Ikeda Y. Physicochemical evaluation and developability assessment of co-amorphous forms of low soluble drugs and comparison to the co-crystals. Chem Pharm Bull 2016;64:1739-46.
12. Vioglio CP, Chierotti MR, Gobetto R. Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges. Adv Drug Delivery Rev 2017;117:86-110.
13. Childs SL, Stahlby GP, Park A. The salt-cocrystal continuum: the influence of crystal structure on ionization state. Mol Pharm 2007;4:323-38.
14. Grothe E, Meekes H, Vleg E, Horst JH, Gelder R. Solvates, salts, and cocrystals: a proposal for a feasible classification system. Cryst Growth Des 2016;16:3237-43.
15. Nie H, Byrn SR, Zhou QT. Stability of pharmaceutical salts in solid oral dosage forms. Drug Dev Ind Pharm 2017;43:1215-28.
16. Jones W, Motherwell WDS, Trask AV. Pharmaceutical cocrystals: an emerging approach to physical property enhancement. MRS Bull 2006;31:875-9.
17. Desiraju GR. Supramolecular synthons in crystal engineering—a new organic synthesis. Angewandte Chemie International Edition 1999;5:34:2311-27.
18. Pindelska E, Sokal A, Kolodziejski W. Pharmaceutical cocrystals, salts and polymorphs: advanced characterization techniques. Adv Drug Delivery Rev 2017;117:111-46.
19. Dourroumis D, Ross SA, Nokhodchi A. Advanced methodologies for cocrystal synthesis. Adv Drug Delivery Rev 2017;117:178-95.
20. Peltonen L. Practical guidelines for the characterization and quality control of pure drug nanoparticles and nano-cocrystals in the pharmaceutical industry. Adv Drug Delivery Rev 2018;131:101-15.
21. Gajda M, Nartowski KP, Pluta J, Karolewicz B. Continuous, one-step synthesis of pharmaceutical cocrystals via hot-melt extrusion from neat to matrix-assisted processing-state of the art. Int J Pharm 2019;558:426-40.
22. Shan N, Zaworotko MJ. The role of cocrystals in pharmaceutical science. Drug Discovery Today 2008;13:440-6.
23. Atipamula S, Banerjee R, Bansal AK, Bradka K, Cheney ML, Choudhury AR, et al. Polymorphs, salts, and cocrystals: what’s in a name? Cryst Growth Des 2012;12:2:147-52.
24. Shankar SJ, Gowda JBH, Akshatha RS, Metikurki B. Co-crystallization: a novel approach to enhance the dissolution of poorly soluble drugs. Indo Am J Pharm Res 2019;9:3132-44.
25. Rodrigues M, Baptista B, Lopes JA, Sarraguça MC. Pharmaceutical cocrystallization techniques. Advances and challenges. Int J Pharm 2018;547:404-20.
26. Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des 2009;9:2950-67.
27. Kuminek G, Rodriguez Hornedo N, Siedler S, Rocha HV, Caffini SL, Cardoso SG. How cocrystals of weakly basic drugs and acidic coformers might modulate solubility and stability. Chem Commun (Camb) 2016;52:5832-5.
28. Bell RG, Kott L. Chapter 17 regulatory considerations in dissolution and drug release of BCS class II and IV compounds. Poorly Soluble Drugs: Dissolution and Drug Release. Pan Stanford Publishing; 2017. p. 573-602.
29. Basavoji S, Bostrom D, Velaga SP. Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization. Pharm Res 2008;25:530-41.
30. Aakeroy CB, Fasulo ME, Desper J. Cocrystal or salt: does it really matter? Mol Pharm 2007;4:317-22.
31. Brittain HG. Pharmaceutical cocrystals: the coming wave of new drug substances. J Pharm Sci 2013;102:311-7.
32. Babu JN, Nangia A. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst Growth Des 2011;11:2662-79.
33. Bevill JM, Vlahova IP, Smit JP. Polymorphic cocrystals of nutraceutical compound p-coumaric acid with nicotinamide: characterization, relative solid-state stability, and conversion to alternate stoichiometries. Cryst Growth Des 2014;14:1438-48.
34. Awtry EH, Loscalzo J. Aspirin chapter 60. Circulation 2000;101:1206-18.
35. Born G, Patrone C. Antiplatelet drugs. Br J Pharmacol 2006;147:241-51.
36. Oburn SM, Ray OA, MacGillivray LR. Elusive nonsolvated cocrystals of aspirin: two polymorphs with bipyrkline discovered with the assistance of mechanochemistry. Cryst Growth Des 2018;18:2495-501.
37. Darwish S, Zeiglinski J, Krishna GR, Shaikh R, Khaishihe M, Walker GM, et al. A new 1:1 drug-drug cocrystal of theophylline and aspirin: discovery, characterization, and construction of ternary phase diagrams. Cryst Growth Des 2018;18:7526-32.
38. Ray O. The generation of three novel aspirin co-crystals. Honors Theses at the University of Iowa; 2018. p. 1-22.
39. Kulkarni A, Shete S, Hol V, Bachhav R. Novel pharmaceutical cocrystal of telmisartan and hydrochlorothiazide. Asian J Pharm Clin Res 2020;13:104-12.
40. Budiman A, Husni P, Shafira, Alfaraziah TQ. The development of glibenclamide-saccharin cocrystal tablet formulations to increase the dissolution rate of the drug. Int J Appl Pharm 2019;11:359-64.
41. Thenge R, Patel R, Kayande N, Mahajan N. Co-crystals of carvedilol: preparation, characterization and evaluation. Int J Appl Pharm 2020;12:42-9.
42. Budiman A, Megantara S, Apriliani A. Solid dosage form development of glibenclamide-aspartame cocrystal using the solvent evaporation method to increase the solubility of glibenclamide. Int J Appl Pharm 2019;11:150-4.
43. Raghuram R, Alam Ms, Prasad M, Khanduri CH. Pharmaceutical cocrystal of prulifloxacin with nicotinamide. Int J Appl Pharm 2014;6:180-4.
44. Zhang X, Sun F, Zhang T, Jia J, Su H, Wang C, et al. Three pharmaceuticals cocrystals of adefovir: syntheses, structures and dissolution study. J Mol Struct 2015;100:395-400.
45. Ranjan S, Devarapalli R, Kundu S, Vangala VR, Ghosh A, Reddy CM. Three new hydrochlorothiazide cocrystals: Structural analyses and solubility studies. J Mol Struct 2017;1133:405-10.
46. Nechipadappu SK, Trivedi DR. Cocrystal of nutraceutical sinapic acid with active pharmaceutical ingredients ethenzamide and 2-chloro-4-nitrobenzoic acid: equilibrium solubility and stability study. J Mol Struct 2018;1171:898-905.
47. Hendrawan S, Veriansyah B, Widjojokusumo E, Soewandhi SN, Wikarsa S, Tjandrawinata RR. Physicochemical and mechanical properties of paracetamol cocrystal with 5-nitrosophthalic acid. Int J Pharm 2016;497:106-13.